

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Cytokine Pharmasciences, Inc.	03/02/2012

RECEIVING PARTY DATA

Name:	Ferring BV
Street Address:	Polaris Avenue 144
Internal Address:	.
City:	.Hoofddorp
State/Country:	NETHERLANDS
Postal Code:	.2132 JX

PROPERTY NUMBERS Total: 45

Property Type	Number
Application Number:	11081728
Application Number:	11766794
Application Number:	11931738
Application Number:	12560402
Application Number:	12879144
Application Number:	12961657
Application Number:	13133492
Application Number:	13133485
Patent Number:	5574040
Patent Number:	5599984
Patent Number:	5620983
Patent Number:	5654186
Patent Number:	5703086
Patent Number:	5733932

CH \$1800.00 11081728

Patent Number:	5750573
Patent Number:	5753684
Patent Number:	5808068
Patent Number:	5840893
Patent Number:	5840305
Patent Number:	5846796
Patent Number:	5849793
Patent Number:	5849794
Patent Number:	5854289
Patent Number:	5859062
Patent Number:	6008255
Patent Number:	6022900
Patent Number:	6054121
Patent Number:	6143728
Patent Number:	6174526
Patent Number:	6180676
Patent Number:	6248787
Patent Number:	6255046
Patent Number:	6297253
Patent Number:	6319894
Patent Number:	6413939
Patent Number:	6595851
Patent Number:	6649797
Patent Number:	6673777
Patent Number:	6759036
Patent Number:	6906076
Patent Number:	7244765
Patent Number:	7291647
Patent Number:	7741372
Patent Number:	7795314
Patent Number:	7863334

CORRESPONDENCE DATA

Fax Number: (877)769-7945
Phone: (212) 765-5070
Email: apsi@fr.com

PATENT
REEL: 027827 FRAME: 0426

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: S. Peter Ludwig
Address Line 1: FISH & RICHARDSON P.C.
Address Line 2: P.O.BOX 1022
Address Line 4: MINNEAPOLIS, MINNESOTA 55440-1022

ATTORNEY DOCKET NUMBER:	27521-0022001
-------------------------	---------------

NAME OF SUBMITTER:	Theresa M. King
--------------------	-----------------

Total Attachments: 4
source=FERRING_ASSIGN#page1.tif
source=FERRING_ASSIGN#page2.tif
source=FERRING_ASSIGN#page3.tif
source=FERRING_ASSIGN#page4.tif

ASSIGNMENT

For valuable consideration,

Cytokine Pharmasciences, Inc., a Delaware corporation, having a place of business at: Walnut Hill Plaza, 150 South Warner Road, Suite 420, King of Prussia, PA 19406, (hereinafter referred to as the “ASSIGNOR”), hereby assigns to:

Ferring BV a Dutch private company, having a place of business at: Polaris Avenue 144 2132 JX Hoofddorp, The Netherlands, (hereinafter referred to as the “ASSIGNEE”), its successors and assigns (collectively hereinafter called “the Assignee”), the entire right, title and interest throughout the world in the inventions and improvements which are subjects of the pending United States patent applications and the issued United States patents listed on the annexed Schedule A, and this assignment including said applications and patents, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to recover for past infringement thereof, and to claim priority based on the filing date of said applications and patents under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and Assignor authorizes the Assignee to apply in all countries in Assignor’s name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventors’ certificates for said inventions and improvements; and Assignor agrees for ourselves and our respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment.

I declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that I have signed this document as my own free act and that all of the foregoing is true and correct.

Cytokine Pharmasciences, Inc.,

By: *Pankaj Anand* FEBRUARY 2012
Name: L. AKHAWALA
Title: TREASURER.

Witnessed by:

Name: *Abhinav*
GENEVIENE BILUTIS

Date: 3/2/2012

Name: *George*
George Heibaf

Date: March 2, 2012

SCHEDULE A

Client Ref.	Patent No.	Issued	Title
0301	5574040	11/12/1996	Pyrimidine Compounds and Methods of Use to Derivatize Neighboring Lysine Residues in Proteins Under Physiologic Conditions
0102	5599984	2/4/1997	Guanyldrazones for Treating Inflammatory Conditions
0302B	5620983	4/15/1997	Compounds and Methods of Use to Derivatize Neighboring Lysine Residues in Proteins Under Physiological Conditions
0401	5654186	8/5/1997	Blood-Borne Mesenchymal Cells
0302A	5703086	12/30/1997	Compounds and Methods of Use to Derivatize Neighboring Lysine Residues in Proteins Under Physiological Conditions
0302	5733932	3/31/1998	Compounds and Methods of Use to Derivatize Neighboring Lysine Residues in Proteins Under Physiological Conditions
0103	5750573	5/12/1998	Guanyldrazones and Their Use to Treat Inflammatory Conditions
0103C	5753684	5/19/1998	Guanyldrazones and Their Use to Treat Inflammatory Conditions
0305	5808068	9/15/1998	HIV Nuclear Localization Inhibitors
0303	5840893	11/24/1998	Compounds and Methods for Use to Treat Infectious Diseases
0501	5840305	11/24/1998	Treatment of HIV-Infection by Interfering With Host Cell Cyclophilin Receptor Activity
0401B	5846796	12/8/1998	Blood-Borne Mesenchymal Cells
0306	5849793	12/15/1998	HIV Matrix Protein Tyrosine Position 29 Pocket Binders
0103G	5849794	12/15/1998	Guanyldrazones and Their Use to Treat Inflammatory Conditions
0104	5854289	12/29/1998	Guanyldrazones and Their Use to Treat Inflammatory Conditions
0103E	5859062	1/12/1999	Guanyldrazones and Their Use to Treat Inflammatory Conditions
0103D	6008255	12/28/1999	Guanyldrazones and Their Use to Treat Inflammatory Conditions
0103B	6022900	2/08/2000	Guanyldrazones and Their Use to Treat Inflammatory Conditions
0402A	6054121	4/25/2000	Modulation of Immune Responses in Blood-borne Mesenchymal Cells
0105	6143728	11/7/2000	Guanyldrazones Useful for Treating Diseases Associated with T-cell Activation
0401A	6174526	1/16/2001	Blood-Borne Mesenchymal Cells
0103A	6180676	1/30/2001	Guanyldrazones and Their Use to Treat Inflammatory Conditions
0103H	6248787	6/19/2001	Guanyldrazones and Their Use to Treat Inflammatory Conditions
0902	6255046	7/3/2001	Inducible Phosphofructokinase and the Warburg Effect
0304	6297253	10/2/2001	Compounds and Methods for Use to Treat Infectious Diseases
0106	6319894	11/20/2001	Complexes and Compositions of Fetuin with Therapeutic Agents
0901	6413939	7/02/2002	Inducible Phosphofructokinase and the Warburg Effect
0902A	6595851	7/22/2003	Inducible Phosphofructokinase and the Warburg Effect

0304A	6649797	11/18/2003	Compounds and Methods for Use to Treat Infectious Diseases
0105A	6673777	1/6/2004	Guanylhydrazones Useful for Treating Diseases Associated with T-cell Activation
0404	6759036	7/6/2004	Fibrocyte-Based Cellular Therapy Formulations
0304	6906076	6/14/2005	Compounds and Methods for Use to Treat Infectious Diseases
0112	7244765	7/17/2007	Guanylhydrazone Salts, Compositions, Processes of Making and Methods of Using
0113	7291647	11/6/2007	Guanylhydrazone Compounds, Compositions, Methods of Making and Using
0105B	7741372	6/22/2010	Guanylhydrazones Useful for Treating Diseases Associated with T-cell Activation
0114	7795314	9/14/2010	HMGB1 Expression and Protective Role of Semapimod in NEC
0113	7863334	1/4/2011	Guanylhydrazone Compounds, Compositions, Methods of Making and Using
Client Ref.	Application No.	Filed	Title
0110	11/081728	3/17/2005	Guanylhydrazone As Antifungal and Antibacterial
0112	11/766794	6/22/2007	Guanylhydrazone Salts, Compositions, Processes of Making and Methods of Using
0112	11/931738	10/31/2007	Guanylhydrazone Salts, Compositions, Processes of Making and Methods of Using
0115	12/560402	9/15/2009	Semapimod In Poi and Guanylhydrazones for Treatment of Post-Operative Intestinal Inflammation
0114	12/879144	9/10/2010	HMGB1 Expression and Protective Role of Semapimod in NEC
0113	12/961657	12/7/2010	Guanylhydrazone Compounds, Compositions, Methods of Making and Using
0310P, WO	13/133492	6/8/2011	Novel Antiviral Compounds, Compositions, and Methods of Use
0309P, WO	13/133485	6/8/2011	Novel Antiviral Compounds, Compositions, and Methods of Use